Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

In recent years, lutetium-177 ((177)Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we report on an early experience of (177)Lu-PSMA therapy with an evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Assadi, Majid, Rezaei, Samira, Jafari, Esmail, Rekabpour, Seyed Javad, Ravanbod, Mohammad Reza, Zohrabi, Farshad, Amini, AbdulLatif, Keshmiri, Saeid, Dadgar, Habibollah, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067127/
https://www.ncbi.nlm.nih.gov/pubmed/32190017
http://dx.doi.org/10.4103/wjnm.WJNM_20_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067127/
https://www.ncbi.nlm.nih.gov/pubmed/32190017
http://dx.doi.org/10.4103/wjnm.WJNM_20_19

Ejemplares similares